Presented by AZBio and the Arizona Commerce Authority with support from the City of Phoenix and the Flinn Foundation CELEBRATING LIFE & SCIENCE A Special Broadcast Event on September 16, 2020 More Details Are Coming Soon. Please register so that we can provide updates as they become available.. We’re Celebrating Arizona’s Educators, Innovators,Companies, and […]
Presented by the Arizona Commerce Authority and the City of Phoenix The AZBio Awards Celebrate Arizona’s leading Educators, Innovators and Companies. Judging Timeline: January 12, 2025 – Nominations for the 2025 AZBio Awards open June 1, 2025 – Nominations Close July 2025 – Honorees Notified October 15, 2025 – AZBio Awards Click here for a […]
June is fast approaching and that means the first ever middle of the calendar year NIH SBIR/STTR Omnibus grants solicitation is coming!
AZBio and its partners have programs strategically designed to help improve access to capital for our Arizona Life Science Industry and to preserve capital through AZBio Purchasing Power Programs. How well they work depends on you.
In January 2013 at TEDx Beacon Street, Harvard Business School’s Rosabeth Moss Kanter shared Six Keys to Leading Positive Change. Let’s look at how can we apply them to grow our Bioscience and Healthcare Industry here in Arizona so we can individually and collectively keep things moving up.
On March 21, 2011, I was granted the opportunity by AZBio’s Board of Directors to become our association’s president and ceo. What’s happened since then is a testament to what can happen when we come together as a community. —- Joan Koerber-Walker
2013 will soon take its place in the history books with fireworks and strains of Auld Lang Syne. As 2014 approaches, let’s look into our crystal ball for some predictions of what the new year may have in store…
Arizona is home to a leading “emerging bioscience sector”…yet for most non-Arizonans, and many residents of the state, the industry and its value as a scientific and economic contributor is still unrecognized.
From Small Molecules to Large Biologics: a look at the impact of relative size and complexity and how it impacts the biosimilar debate in the states.